Definitive Healthcare (NASDAQ:DH) Price Target Cut to $4.00 by Analysts at Canaccord Genuity Group

Definitive Healthcare (NASDAQ:DH) had its price target reduced by Canaccord Genuity Group from $5.00 to $4.00 in a research note released on Monday,Benzinga reports. Canaccord Genuity Group currently has a hold rating on the stock.

A number of other equities research analysts have also recently commented on the company. Robert W. Baird set a $4.00 target price on Definitive Healthcare in a research note on Friday, August 8th. Stifel Nicolaus upped their price target on shares of Definitive Healthcare from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Friday, August 8th. William Blair upgraded shares of Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.23.

Definitive Healthcare Price Performance

Shares of DH opened at $2.85 on Monday. Definitive Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $5.68. The firm’s 50-day simple moving average is $3.44 and its two-hundred day simple moving average is $3.58. The stock has a market cap of $407.95 million, a PE ratio of -1.71 and a beta of 1.61. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.65 and a current ratio of 1.65.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $60.05 million during the quarter, compared to analyst estimates of $59.51 million. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.14%. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS. Q4 2025 guidance at 0.050-0.060 EPS. Analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Several institutional investors have recently made changes to their positions in DH. Cubist Systematic Strategies LLC boosted its stake in shares of Definitive Healthcare by 2,456.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 144,284 shares of the company’s stock worth $417,000 after acquiring an additional 138,640 shares during the last quarter. Nuveen LLC bought a new position in Definitive Healthcare in the 1st quarter worth $300,000. Allianz Asset Management GmbH raised its holdings in Definitive Healthcare by 70.0% in the 1st quarter. Allianz Asset Management GmbH now owns 42,000 shares of the company’s stock worth $121,000 after purchasing an additional 17,300 shares during the period. Victory Capital Management Inc. lifted its position in Definitive Healthcare by 519.3% during the first quarter. Victory Capital Management Inc. now owns 223,941 shares of the company’s stock valued at $647,000 after purchasing an additional 187,780 shares in the last quarter. Finally, Tocqueville Asset Management L.P. grew its holdings in Definitive Healthcare by 32.5% during the first quarter. Tocqueville Asset Management L.P. now owns 265,000 shares of the company’s stock valued at $766,000 after purchasing an additional 65,000 shares during the period. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.